RecruitingPhase 2NCT07283822

Amping up With PemJAK

A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas

Sponsor

Seda S. Tolu

Enrollment

53 participants

Start Date

Dec 3, 2025

Study Type

INTERVENTIONAL

Conditions

Non-Hodgkin Lymphoma Hodgkin Disease Lymphoma Non-Hodgkin Lymphoma Refractory/ Relapsed Hodgkin Disease Recurrent Gray Zone Lymphoma

Summary

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

Eligibility

Min Age: 18 YearsMax Age: 95 Years

Plain Language Summary

Simplified for easier understanding

This study (called PemJAK) is testing a combination of pembrolizumab (an immunotherapy drug) and a JAK inhibitor for people with relapsed or refractory lymphoma — lymphoma that has come back or stopped responding to prior treatment. Multiple lymphoma subtypes are included. **You may be eligible if...** - You have relapsed or refractory Hodgkin lymphoma (HL), primary mediastinal B-cell lymphoma (PMBCL), grey zone lymphoma (GZL), or certain types of T-cell lymphoma (including PTCL, CTCL subtypes like mycosis fungoides or Sézary syndrome) - You have received at least one prior systemic treatment - If you have ALCL, you must have previously received a CD30-directed therapy **You may NOT be eligible if...** - You have not received prior systemic therapy - You do not have a confirmed lymphoma subtype covered by this study - You have other medical conditions that would make immunotherapy unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRuxolitinib

Patients will receive the study drug ruxolitinib for as long as the disease responds, for up to a maximum of one year (or 17 cycles). After study treatment with ruxolitinib is finished, the study doctor will continue to watch for side effects and follow the condition for one year. If any side effects are experienced, the study doctor will follow up until resolution or stabilization of the side effect.

DRUGPembrolizumab

Pembrolizumab immunotherapy will be administered intravenously at 200 mg once every 21 days. Subjects will receive pembrolizumab for as long as the disease responds, up to a maximum of one year (or 17 cycles). Each cycle is 21 days long.

Locations(1)

Columbia University Irving Medical Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07283822

Related Trials

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT047398131 location

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

NCT053894231 location

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716127 locations

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT032236101 location

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT0516951526 locations